DAFNA Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

DAFNA Capital Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-25,907	Closed	-$249K	–	99
2016 Q2	$249K	Buy	+25,907	New	+$250K	0.2%	73
2014 Q2	–	Sell	-26,151	Closed	-$391K	–	52
2014 Q1	$391K	Buy	+26,151	New	+$470K	0.34%	39

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

DVC

Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

DAFNA Capital Management's AVEO Position: Q3 2016 in Review

DAFNA Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2016, closing a stake of 25,907 shares — an estimated $249K sold.

DAFNA Capital Management first reported a position in AVEO in Q1 2014 and held it in 2 quarters. The position peaked at $391K in Q1 2014. 44 funds tracked by Wall St. Rank hold AVEO as of Q3 2016.

DAFNA Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
DAFNA Capital Management sold 25,907 AVEO Pharmaceuticals, Inc. shares in Q3 2016, an estimated $249K.
DAFNA Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2014 and held it in 2 quarters.
DAFNA Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $391K in Q1 2014.
44 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2016.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.